Teva Pharmaceutical Industries stock wins FDA approval for IGALMI
Published on 11/17/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory milestone and next steps
- The FDA approved IGALMI for at-home treatment of acute agitation in adults with specified psychiatric disorders.
- Teva reported 1,160 treated agitation episodes among 102 patients in the Phase 3 at-home trial.
- Commercialization plans for the at-home use are due at a later date.
Teva Pharmaceutical Industries Ltd. said on Monday, November 16, that the U.S. Food and Drug Administration approved IGALMI, a dexmedetomidine sublingual film, for at-home use by adults with agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The company described it as the first FDA-approved treatment for this use outside a healthcare setting, according to Teva's press release.
What the approval changes
IGALMI can now be self-administered at home during an agitation episode, while its existing use under healthcare-provider supervision remains part of the product's profile. Teva said the approval addresses a treatment need in neuroscience and supports its Pivot to Growth strategy.
The Phase 3 SERENITY At-Home trial treated 1,160 agitation episodes in 102 patients over 12 weeks. Teva reported consistent tolerability with repeat dosing and no treatment discontinuations because of tolerability. The most commonly reported adverse events were sleepiness, dry mouth, dizziness, and oral paresthesia or hypoesthesia.
Commercialization remains next
Teva acquired IGALMI in late October 2026 and submitted the application for at-home use on January 14, 2026. The company said it would announce commercialization plans for the new indication at a later date, leaving launch execution as the next business step.
The approval adds a regulatory milestone to Teva's neuroscience portfolio, but commercial uptake will depend on execution, competition, and the company's broader financial and operating performance. Teva's U.S. listing places the company in the broader S&P 500 market environment.
Teva Pharmaceutical Industries
- Company: Teva Pharmaceutical Industries Ltd.
- ISIN: US8816242098
- Ticker: TEVA
- Exchange: New York Stock Exchange and Tel Aviv Stock Exchange
- Regulatory event: U.S. FDA approval of IGALMI for at-home use on November 16, 2026
More news and analyses on Teva Pharmaceutical Industries stock
